Industry news, page-102

First 102 Last

Share
Profile

Follow
thevinnys

1,958 Posts.

4359

19/09/21

07:17

Post #: 56180342
Share

Originally posted by ma420: ↑

We all know that IHL is in a wonderful spot with its CBD and Psychedelic trials. Just want to share this report that Roth Capital has on Cybin which is NYSE listed.

What I like about this report is that it shows how well Roth research team understands the market and the competition (they have Buy rating on Cybin and Compass pathways). While Roth Investment Banking side would work with IHL for the listing on NASDAQ, this report demonstrates that their research (separated by a Chinese wall) is able to provide a solid report which would be read by instos and retail investors in this space. Further, their trading desk would obviously market IXHL to their clients who are interested in this space.

I would suggest you to read this report to get a big picture of the industry, the competitive landscape, the pros and cons of various Psychedelics options, delivery mechanisms etc.,. Also imagine very soon, these reports will be mentioning IXHL as part of the competition

https://drive.google.com/file/d/1nJnXE2qOuUt1i8PRJxj84kK0Ct3tVJAO/view

(Definitely not cross promoting Cybin!)

Expand

Hey @ma420

Very interesting research and valuation analysis done on Cybin.
Roth Capital have five analyst / researchers covering the Health Care Sector
Looking forward to see their work/research, analysis and values on IXHL

Four of the 5 are PHD's
https://www.roth.com/sectors/healthcare#sector_research_eq

Interesting couple weeks ahead!

Good luck @ma420

IHL Price at posting: 40.0¢ Sentiment: Buy Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

NWC

New World Resources inks complete PFS for Antler Copper Project in Arizona, USA

AI stocks: What to expect in 2024-25

ATH

Trial for Alterity's neurodegenerative drug ATH434 shows reduced disability

LRL

Labyrinth shares rocket by 219% on news of Comet Vale and Vivien gold project acquisitions

CTT

Cettire shares jump on FY24 revenue growth up 80% vs pcp – but stock still badly bruised